Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL | MicrobiomeTrials← Back to trialsNCT07575919
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-01-01Est. Completion: 2026-12-31
Enrollment target: 20 participants Locations- Chinese PLA General Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
Heart Failure With Preserved Ejection Fraction (HFpEF
This study will investigate whether intravenous (IV) iron improves symptoms, exercise capacity, and quality of life in p…
Saint Helier, JerseyEst. completion Jul 2029
Macrophage Activation SyndromePrimary Hemophagocytic Lymphohistiocytosis
Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile,…
Bethesda, United StatesEst. completion Dec 31, 2026
Phase 3
Recruiting
Lung Non-Small Cell CarcinomaLung Non-Small Cell Squamous CarcinomaLung Non-Squamous Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of …
Anchorage, United StatesEst. completion Jan 31, 2027